Material Event Form 8 K

Item 8.01 Other Events.

Reference is hereby made to the Current Report on Form 8-K filed by CERo Therapeutics Holdings, Inc. (the "Company") on December 31, 2024, pursuant to which the Company reported the receipt of proceeds exercises of certain warrants to purchase shares of Series A Preferred Stock and issuances of shares pursuant to the Company's committed equity financing facility (the "Equity Line") through December 30, 2024.

As a result of the receipt of such proceeds and the receipt of additional proceeds from sales pursuant to the Equity Line through January 6, 2025, the Company now reports a cash balance of approximately $5.463 million as of January 7, 2025.